Orchid Pharma Limited

ORCHPHARMA

INE191A01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:48 2024-04-29 am EDT			5-day change	1st Jan Change
1,088 ^INR	+0.34%		+3.27%	+52.70%

Apr. 12	Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director	CI
Feb. 23	Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	CI

Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director

April 12, 2024 at 09:42 am EDT

Orchid Pharma Limited announced resignation of Mr. Mudit Tandon as Independent Director of the company with effect from close of business hours of April 12, 2024, due to other commitments and personal reasons.

Latest news about Orchid Pharma Limited

Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director	Apr. 12	CI
Orchid Pharma Receives United States Food and Drug Administration Approval for Its Novel Invention	Feb. 23	CI
Transcript : Orchid Pharma Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep'	Jan. 30	CI
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer	Dec. 16	CI
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer	Dec. 14	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent)	23-10-20	CI
Orchid Pharma Ties Up with GARDP to Manufacture Antibiotic for Certain Gram-Negative Infections	23-09-12	MT
Orchid Pharma Limited Enters into Manufacturing Sub License Agreement with Global Antibiotic Research & Development Partnership	23-09-12	CI
Orchid Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Orchid Pharma Raises INR4 Billion Via Qualifed Institutional Placement	23-06-28	MT
Orchid Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-10	CI
CARE Upgrades Rating on Orchid Pharma's Long-term Bank Financing to BBB; Outlook Stable	23-02-09	MT
Orchid Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-09	CI
Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director	23-02-01	CI
Orchid Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-14	CI
Orchid Pharma : UK drugs regulator to halt approvals for Indian clinical trials firm	16-07-01	RE

Chart Orchid Pharma Limited

Duration

Period

More charts

Company Profile

Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,088 INR

Average target price

1,130 INR

Spread / Average Target

+3.86%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ORCHID PHARMA LIMITED	+52.70%	659M
ELI LILLY AND COMPANY	+26.47%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.33%	352B
MERCK & CO., INC.	+19.35%	332B
ABBVIE INC.	+4.23%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.04%	145B

Other Pharmaceuticals